Nazartinib; EGF816; NVS-816

Aha kemịkalụ:

(R, E) -N- (7-chloro-1- (1- (4- (dimethylamino)ma-2-enoyl)azepan-3-yl) -1H-benzo [d] imidazole-2-yl) 2-methylisonicotinamide

Koodu Ọchịchọ:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

Koodu InChi:

InChi=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15 -32 (17-20) 23 (34) 11-7-14-31 (2) 3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3 , (H,29,30,35)/b11-7+/t20-/m1/s1

Igodo InChi:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Okwu:

Nazartinib, EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2

Solubility:Soluble na DMSO

Nchekwa:0 - 4 Celsius C maka obere oge (ụbọchị ruo izu), ma ọ bụ -20 Celsius maka ogologo oge (ọnwa)

Nkọwa:

Nazartinib, nke a makwaara dị ka EGF816 na NVS-816, bụ ọnụ ọnụ dịnụ, enweghị ike ịgbanwe, ọgbọ nke atọ, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, nwere ọrụ antineoplastic. EGF816 na-ejikọta ọnụ ma gbochie ọrụ nke ụdị mutant nke EGFR, gụnyere mutant T790M EGFR, si otú a na-egbochi mgbasa ozi EGFR na-agbasa. Nke a nwere ike ịkpata ọnwụ cell ma gbochie uto tumor na EGFR-overexpressing tumor cell. EGF816 na-akacha mma na-egbochi ụdị EGFR gbanwetụrụ gụnyere T790M, ngbanwe nke abụọ enwetara, ma nwee ike nweta uru ọgwụgwọ na etuto ahụ nwere nguzogide mgbasa ozi T790M ma e jiri ya tụnyere ndị ọzọ EGFR tyrosine kinase inhibitors.

Ebumnuche: EGFR